2023 U.S. Vaccine Market Report Unveils Growth Trends and Forecasts Through 2030: COVID-19 Vaccines, Adult Vaccination Rates, Influenza Vaccine Production
18 janv. 2024 05h58 HE
|
Research and Markets
Dublin, Jan. 18, 2024 (GLOBE NEWSWIRE) -- The "2023 U.S. Vaccine Market Report" report has been added to ResearchAndMarkets.com's offering. In a comprehensive analysis of the U.S. vaccine market,...
Vaxcyte Appoints Whitney Jones as Chief People Officer
16 janv. 2024 16h01 HE
|
Vaxcyte, Inc.
-- Ms. Jones Joins Vaxcyte With Over 20 Years of Experience Leading People and Culture Strategies Across Multiple Industries -- SAN CARLOS, Calif., Jan. 16, 2024 (GLOBE NEWSWIRE) -- Vaxcyte, Inc....
Intravacc Awarded US$ 633K CARB-X Funding to Develop a Vaccine that Prevents Gonorrhea Infections
16 janv. 2024 06h00 HE
|
Intravacc B.V.
Intravacc secures $633K funding from CARB-X to develop a vaccine against or Neisseria gonorrhoeae.
Antivenom Global Market Report 2023
04 janv. 2024 16h38 HE
|
Research and Markets
Dublin, Jan. 04, 2024 (GLOBE NEWSWIRE) -- The "Antivenom Global Market Report 2023" report has been added to ResearchAndMarkets.com's offering.Antivenom, also known as antivenin, is an antibody...
Vaxcyte Provides Clinical and Regulatory Progress Update on Potential Best-in-Class Pneumococcal Conjugate Vaccine (PCV) Franchise
04 janv. 2024 16h01 HE
|
Vaxcyte, Inc.
-- Company Doses First Participants in Phase 2 Portion of Ongoing VAX-31 Phase 1/2 Study in Adults Following Independent Review of Phase 1 Safety and Tolerability Data; Topline Safety, Tolerability...
Dyadic to Attend J.P. Morgan 42nd Annual Healthcare Conference
02 janv. 2024 08h30 HE
|
Dyadic International, Inc.
JUPITER, Fla., Jan. 02, 2024 (GLOBE NEWSWIRE) -- Dyadic International, Inc. (“Dyadic”, or the “Company”) (NASDAQ: DYAI), a global biotechnology company focused on building innovative microbial...
Intravacc launches new website with a wealth of scientific knowledge to elevate vaccine innovation
20 déc. 2023 06h10 HE
|
Intravacc B.V.
Intravacc's new website offers an immersive user experience, showcasing their CDMO expertise vaccine platforms and a hub for scientific publications.
Quadrivalent Virus-Like Particle (VLP) Vaccine Emerging Drug Insights and Market Forecasts, 2019-2022 and 2023-2032
14 déc. 2023 10h03 HE
|
Research and Markets
Dublin, Dec. 14, 2023 (GLOBE NEWSWIRE) -- The "Quadrivalent VLP vaccine Emerging Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report...
FLUARIX Research Report 2023: A Vaccine Indicated for Active Immunization to Prevent Disease Caused by Influenza A Subtype Viruses and Type B Viruses - Drug Insights and Market Forecasts 2019-2032
12 déc. 2023 05h13 HE
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "FLUARIX QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...
FLUMIST Research Report 2023: The Most Widely Available Quadrivalent Live Attenuated Influenza Vaccine - Drug Insights and Market Forecasts 2019-2032
12 déc. 2023 05h08 HE
|
Research and Markets
Dublin, Dec. 12, 2023 (GLOBE NEWSWIRE) -- The "FLUMIST QUADRIVALENT Drug Insight and Market Forecast - 2032" report has been added to ResearchAndMarkets.com's offering.This report provides...